Please note, this OEL/ADE monograph also applies to doxazosin mesylate (CAS RN 77883-43-3) and also includes the pediatric ADE. Doxazosin is used benign prostate growth and high blood pressure. Doxazosin, a quinazoline compound, selectively inhibits the alpha(1)-subtype of alpha adrenergic receptors, and it binds highly to alpha(1A) adrenoceptor and to the subtype predominant in the prostate gland, alpha(1C) adrenoceptor. Blockade of the alpha(1) adrenoceptor decreases smooth muscle tone in the prostate and bladder. It also has antagonistic effects on phenylephrine (alpha (1) agonist)-induced contractions.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Doxazosin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.